Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, ...
In addition to its cell-cycle function, several observations suggest a role of B-Myb in the DNA damage response. Using chicken DT40 cells as a model system, we have shown that B-Myb is required for ...
“This makes C/EBPβ an interesting pro-oncogenic player in AML, worthy of further studies.” In this new paper, researcher Karl-Heinz Klempnauer from Westfälische-Wilhelms-Universität discusses recent ...
Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the ...
Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation ...
Ribopeutic Inc. has divulged nucleic acid splicing modulators (particularly, Huntingtin [HTT; HD] [mutant] and/or transcriptional activator Myb [c-Myb]) reported to be useful for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results